Table 2. Univariate and multivariate analyses of the clinicopathological factors and FGFR3 expression associated with the survival of NSCLC patients.
| Variable | Subset | HR (95% CI) | P value |
|---|---|---|---|
| Univariate analysis (N=86) | |||
| Age | ≥60 vs. <60 | 0.945 (0.447–1.999) | 0.883 |
| Smoking | Yes vs. no | 1.554 (0.734–3.291) | 0.249 |
| Gender | Male vs. female | 2.501 (0.950–6.582) | 0.063 |
| Histology type | AC vs. SCC | 0.523 (0.236–1.157) | 0.110 |
| T stage | ≤5 vs. >5 cm | 0.827 (0.351–1.950) | 0.664 |
| N stage | 0 vs. 1, 2, 3 | 1.756 (0.830–3.718) | 0.141 |
| Clinical stage | I, II vs. III | 1.303 (0.601–2.826) | 0.503 |
| EGFR mutation | Yes vs. no | 0.523 (0.236–1.157) | 0.110 |
| FGFR3 | Low vs. high | 0.294 (0.102–0.850) | 0.024 |
| Multivariate analysis (N=86) | |||
| FGFR3 | Low vs. high | 0.294 (0.102–0.850) | 0.024 |
FGFR3, fibroblast growth factor receptor 3; NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence interval; AC, adenocarcinoma; SCC, squamous cell carcinoma; EGFR, epidermal growth factor receptor.